X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-03-04 | TPTX | Turning Point Therapeutics, Inc. | Reich Siegfried | EVP, Chief Scientific Officer | S - Sale+OE | $105.04 | -35,550 | 3,845 | -90% | -$3,734,075 | |||||
2021-03-04 | RVNC | Revance Therapeutics, Inc. | Rankin Aubrey | Pres, Innovation, Tech | S - Sale | $25.43 | -33,119 | 665,405 | -5% | -$842,216 | ||||||
| M | 2021-03-03 | SDGR | Schrodinger, Inc. | Shaw David E | 10% | S - Sale | $83.44 | -100,000 | 8,762,154 | -1% | -$8,343,827 | |||||
| M | 2021-03-03 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Dir | S - Sale | $56.45 | -23,959 | 420,825 | -5% | -$1,352,499 | |||||
| M | 2021-03-03 | ALLK | Allakos Inc. | More Robert J | member - potential 10% group | S - Sale | $114.22 | -32,554 | 2,071,147 | -2% | -$3,718,319 | |||||
| M | 2021-03-03 | IRWD | Ironwood Pharmaceuticals Inc | Denner Alexander J | Dir, 10% | P - Purchase | $10.01 | +775,000 | 16,202,844 | +5% | +$7,758,750 | |||||
2021-03-03 | ABT | Abbott Laboratories | Wainer Andrea F | EVP | S - Sale | $121.79 | -6,200 | 51,550 | -11% | -$755,098 | ||||||
2021-03-03 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $44.78 | -100,000 | 250,390 | -29% | -$4,478,450 | ||||||
2021-03-04 | BPMC | Blueprint Medicines Corp | Durso-Bumpus Debra | Chief People Officer | S - Sale | $86.76 | -1,693 | 30,874 | -5% | -$146,887 | ||||||
| M | 2021-03-03 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale | $91.16 | -1,372 | 11,799 | -10% | -$125,066 | |||||
2021-03-04 | BPMC | Blueprint Medicines Corp | Haviland Kate | COO | S - Sale | $86.77 | -1,952 | 53,948 | -3% | -$169,370 | ||||||
2021-03-04 | BPMC | Blueprint Medicines Corp | Landsittel Michael | CFO | S - Sale | $86.76 | -1,507 | 28,905 | -5% | -$130,749 | ||||||
2021-03-04 | BPMC | Blueprint Medicines Corp | McCain Tracey L | EVP, GC | S - Sale | $86.76 | -1,893 | 32,852 | -5% | -$164,242 | ||||||
2021-03-04 | BPMC | Blueprint Medicines Corp | Murray Christopher K. | SVP, Technical Operations | S - Sale | $86.76 | -1,210 | 18,888 | -6% | -$104,984 | ||||||
2021-03-04 | BPMC | Blueprint Medicines Corp | Rossi Christina | Chief Commercial Officer | S - Sale | $86.77 | -1,359 | 31,723 | -4% | -$117,920 | ||||||
| D | 2021-03-04 | BPMC | Blueprint Medicines Corp | Albers Jeffrey W. | CEO, Pres | S - Sale+OE | $89.28 | -18,986 | 172,448 | -10% | -$1,695,006 | |||||
| D | 2021-03-04 | CLRB | Cellectar Biosciences, Inc. | Caruso James V | Pres, CEO | P - Purchase | $1.70 | +5,100 | 86,401 | +6% | +$8,659 | |||||
| D | 2021-03-03 | SDGR | Schrodinger, Inc. | D'Cruz Cony | EVP, Chief Business Officer | S - Sale+OE | $106.90 | -4,800 | 151,082 | -3% | -$513,120 | |||||
| D | 2021-03-03 | GBIO | Generation Bio Co. | Zimmermann Tracy | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $41.38 | -3,000 | 0 | -100% | -$124,140 | |||||
2021-02-23 | MACK | Merrimack Pharmaceuticals Inc | Crocker Gary L | See Remarks | P - Purchase | $7.20 | +5,000 | 15,104 | +49% | +$36,005 | ||||||
| D | 2021-03-05 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin | Pres, CEO | S - Sale+OE | $30.55 | -1,750 | 807,803 | 0% | -$53,463 | |||||
| M | 2021-03-03 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | P - Purchase | $15.16 | +5,000 | 4,776,794 | 0% | +$75,800 | |||||
| M | 2021-03-03 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | Dir, 10% | P - Purchase | $15.16 | +5,000 | 4,776,794 | 0% | +$75,800 | |||||
2021-03-04 | PHIO | Phio Pharmaceuticals Corp. | Dispersyn Gerrit | Pres, CEO | P - Purchase | $2.56 | +1,953 | 89,281 | +2% | +$5,000 | ||||||
| ADM | 2021-03-01 | ALBO | Albireo Pharma, Inc. | Mattsson Jan | Chief Scientific Officer | S - Sale+OE | $36.85 | -31,470 | 37,574 | -46% | -$1,159,684 | |||||
2021-03-02 | RPRX | Royalty Pharma Plc | Lloyd George W. | EVP, Investments, GC | S - Sale | $46.94 | -125,000 | 651,960 | -16% | -$5,867,148 | ||||||
2021-03-02 | RPRX | Royalty Pharma Plc | Reddoch James F. | EVP, Research, Investments | S - Sale | $46.92 | -100,000 | 325,030 | -24% | -$4,692,158 | ||||||
2021-03-02 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $46.94 | -100,000 | 350,390 | -22% | -$4,694,090 | ||||||
2021-03-03 | NLTX | Neoleukin Therapeutics, Inc. | Walkey Carl | SVP | S - Sale | $11.87 | -1,800 | 1,373,362 | 0% | -$21,360 | ||||||
2021-02-22 | EPIX | Essa Pharma Inc. | Berger Franklin M | Dir | P - Purchase | $27.00 | +57,000 | 957,244 | +6% | +$1,539,000 | ||||||
| D | 2021-03-03 | VTRS | Viatris Inc | Cornwell W Don | Dir | P - Purchase | $13.84 | +3,000 | 3,000 | New | +$41,515 | |||||
| D | 2021-03-02 | ITCI | Intra-Cellular Therapies, Inc. | Marcus Joel S | Dir | S - Sale+OE | $34.93 | -15,250 | 1,263,425 | -1% | -$532,683 | |||||
2021-03-02 | MRTX | Mirati Therapeutics, Inc. | Cherrington Julie M | Dir | S - Sale | $201.01 | -2,000 | 1,475 | -58% | -$402,020 | ||||||
| D | 2021-03-02 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Chief Medical Officer | S - Sale+OE | $22.95 | -15,000 | 43,300 | -26% | -$344,192 | |||||
| DM | 2020-12-28 | STOK | Stoke Therapeutics, Inc. | Liau Gene | EVP Research, Preclinical Dev | S - Sale+OE | $62.93 | -5,344 | 21,351 | -20% | -$336,297 | |||||
2021-03-02 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $10.14 | -154 | 68,677 | 0% | -$1,561 | ||||||
2021-03-02 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $10.16 | -422 | 69,218 | -1% | -$4,288 | ||||||
2021-03-02 | PBYI | Puma Biotechnology, Inc. | Bryce Richard Paul | SEE REMARKS | S - Sale | $10.15 | -422 | 122,088 | 0% | -$4,283 | ||||||
2021-03-02 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $10.14 | -1,238 | 4,431,749 | 0% | -$12,556 | ||||||
| D | 2021-03-03 | ATNX | Athenex, Inc. | Wu Jinn | Dir | S - Sale+OE | $4.75 | -98,000 | 303,208 | -24% | -$465,500 | |||||
2021-03-01 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $2.31 | -10,000 | 6,326,440 | 0% | -$23,100 | ||||||
| DM | 2021-03-02 | TEVA | Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | S - Sale+OE | $10.85 | -15,548 | 15,571 | -50% | -$168,631 | |||||
| D | 2021-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | S - Sale+OE | $10.88 | -1,400 | 0 | -100% | -$15,231 | |||||
2021-03-02 | TEVA | Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun | EVP, Global R, D | S - Sale | $10.82 | -50,000 | 64,064 | -44% | -$540,890 | ||||||
| D | 2021-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing, Portfoli | S - Sale+OE | $10.86 | -606 | 70,058 | -1% | -$6,583 | |||||
| D | 2021-03-03 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, European Commercial | S - Sale+OE | $10.88 | -993 | 11,873 | -8% | -$10,803 | |||||
2021-03-02 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale | $37.60 | -504 | 18,069 | -3% | -$18,950 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Astley-Sparke Philip | Dir | S - Sale | $37.60 | -504 | 9,946 | -5% | -$18,950 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Gut Robert | Dir | S - Sale | $36.98 | -1,300 | 42,001 | -3% | -$48,074 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Soteropoulos Paula | Dir | S - Sale | $37.60 | -504 | 6,364 | -7% | -$18,950 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Balachandran Madhavan | Dir | S - Sale | $37.50 | -505 | 9,945 | -5% | -$18,938 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Meek David D. | Dir | S - Sale | $37.50 | -505 | 6,448 | -7% | -$18,938 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Springhorn Jeremy P. | Dir | S - Sale | $37.50 | -505 | 9,945 | -5% | -$18,938 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Kuta Alexander Edward III | EVP, Operations | S - Sale | $37.00 | -1,206 | 68,871 | -2% | -$44,622 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Klemt Christian | Chief Accounting Officer | S - Sale | $37.03 | -1,350 | 63,604 | -2% | -$49,991 | ||||||
2021-03-02 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $36.94 | -4,974 | 273,777 | -2% | -$183,740 | ||||||
2021-03-03 | ALLK | Allakos Inc. | Tomasi Adam | Pres, COO, CFO | S - Sale | $113.56 | -3,189 | 160,268 | -2% | -$362,143 | ||||||
| DM | 2021-03-03 | ALLK | Allakos Inc. | Rasmussen Henrik S Md | Chief Medical Officer | S - Sale+OE | $116.86 | -61,952 | 125,087 | -33% | -$7,239,844 | |||||
| D | 2021-03-02 | IGMS | Igm Biosciences, Inc. | Keyt Bruce | Chief Scientific Officer | S - Sale+OE | $90.25 | -1,619 | 3,782 | -30% | -$146,115 | |||||
| D | 2021-03-02 | IGMS | Igm Biosciences, Inc. | Chen Daniel Shinyu | Chief Medical Officer | S - Sale+OE | $90.25 | -1,224 | 116,518 | -1% | -$110,466 | |||||
2021-03-02 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Childs John W | Dir | P - Purchase | $85.14 | +10,000 | 2,542,644 | 0% | +$851,370 | ||||||
2021-03-03 | PHIO | Phio Pharmaceuticals Corp. | Ferrara Robert L | Dir | P - Purchase | $3.15 | +682 | 13,000 | +6% | +$2,148 | ||||||
2021-03-03 | PHIO | Phio Pharmaceuticals Corp. | Dispersyn Gerrit | Pres, CEO | P - Purchase | $3.03 | +2,500 | 87,328 | +3% | +$7,575 | ||||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Kassberg Thomas Richard | CBO, EVP | S - Sale+OE | $138.17 | -4,572 | 107,181 | -4% | -$631,713 | |||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Pinion John Richard | See Remarks | S - Sale+OE | $138.17 | -6,198 | 50,237 | -11% | -$856,378 | |||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale+OE | $138.17 | -3,970 | 30,227 | -12% | -$548,535 | |||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | SVP, Controller, PAO | S - Sale+OE | $138.17 | -732 | 16,544 | -4% | -$101,140 | |||||
| DM | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Officer | S - Sale+OE | $138.17 | -3,177 | 27,813 | -10% | -$438,959 | |||||
| M | 2021-03-01 | KROS | Keros Therapeutics, Inc. | Knowles Julius | Dir | S - Sale | $61.13 | -23,690 | 430,283 | -5% | -$1,448,078 | |||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Huang Dennis Karl | EVP, Chief Tech Ops Officer | S - Sale+OE | $138.18 | -4,255 | 40,761 | -9% | -$587,956 | |||||
| D | 2021-03-01 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $68.43 | -33,092 | 85,826 | -28% | -$2,264,443 | |||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Bedrosian Camille L | EVP, Chief Medical Officer | S - Sale+OE | $138.18 | -4,543 | 39,139 | -10% | -$627,752 | |||||
| D | 2021-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Kakkis Emil D | Pres, CEO | S - Sale+OE | $141.80 | -30,000 | 2,885,793 | -1% | -$4,254,000 | |||||
2021-03-02 | CCXI | Chemocentryx, Inc. | Edwards Thomas A. | Dir | S - Sale | $70.06 | -1,100 | 119,857 | -1% | -$77,063 | ||||||
| M | 2021-03-01 | PHAT | Phathom Pharmaceuticals, Inc. | Nabulsi Azmi | COO | S - Sale | $45.88 | -14,500 | 795,533 | -2% | -$665,290 | |||||
2021-03-03 | OTIC | Otonomy, Inc. | Lichter Jay | Dir | S - Sale | $2.70 | -321,180 | 0 | -100% | -$866,544 | ||||||
2021-03-01 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale | $1.14 | -26,728 | 19,054,504 | 0% | -$30,571 | ||||||
2021-03-01 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale | $1.14 | -43,392 | 20,050,848 | 0% | -$49,627 | ||||||
| D | 2021-03-01 | COLL | Collegium Pharmaceutical, Inc | Ciaffoni Joseph | Pres, CEO | S - Sale+OE | $22.67 | -64,768 | 278,307 | -19% | -$1,468,425 | |||||
| DM | 2018-01-12 | COLL | Collegium Pharmaceutical, Inc | Fleming Alison B | Chief Technical Officer | S - Sale+OE | $22.60 | -18,235 | 148,753 | -11% | -$412,169 | |||||
2021-03-03 | XNCR | Xencor Inc | Eckert Celia | VP, GC | S - Sale | $44.94 | -444 | 3,496 | -11% | -$19,955 | ||||||
2021-03-03 | XNCR | Xencor Inc | Desjarlais John R | SVP, CSO | S - Sale | $45.03 | -1,165 | 91,788 | -1% | -$52,454 | ||||||
2021-03-03 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale | $44.88 | -2,850 | 141,064 | -2% | -$127,909 | ||||||
| DM | 2021-03-01 | XNCR | Xencor Inc | Kuch John J | SVP, CFO | S - Sale+OE | $48.71 | -15,870 | 85,415 | -16% | -$772,966 | |||||
2021-03-02 | CLSD | Clearside Biomedical, Inc. | Lasezkay George M | CEO | S - Sale | $3.37 | -6,000 | 433,609 | -1% | -$20,220 | ||||||
2021-03-01 | FOLD | Amicus Therapeutics, Inc. | Crowley John F | COB, CEO | S - Sale | $11.85 | -7,500 | 901,601 | -1% | -$88,881 | ||||||
| D | 2021-03-01 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | COO | S - Sale+OE | $11.84 | -10,514 | 378,857 | -3% | -$124,516 | |||||
2021-03-01 | FOLD | Amicus Therapeutics, Inc. | Whitman Burke W | Dir | P - Purchase | $12.40 | +1,500 | 42,967 | +4% | +$18,600 | ||||||
| D | 2021-03-01 | CLVS | Clovis Oncology, Inc. | Muehl Daniel W | See Remarks | S - Sale+OE | $6.29 | -456 | 47,566 | -1% | -$2,868 | |||||
| DM | 2021-03-01 | ALBO | Albireo Pharma, Inc. | Mattsson Jan | Chief Scientific Officer | S - Sale+OE | $36.85 | -31,470 | 37,574 | -46% | -$1,159,684 | |||||
| M | 2021-03-01 | VNDA | Vanda Pharmaceuticals Inc. | Williams Timothy | SVP, GC | S - Sale | $18.58 | -19,530 | 92,526 | -17% | -$362,850 | |||||
| D | 2021-03-02 | CLVS | Clovis Oncology, Inc. | Ivers-Read Gillian C | See Remarks | S - Sale+OE | $6.29 | -580 | 245,079 | 0% | -$3,648 | |||||
2021-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Wijkstrom Joakim | SVP, CMO | S - Sale | $18.45 | -3,888 | 78,202 | -5% | -$71,729 | ||||||
| M | 2021-03-01 | VNDA | Vanda Pharmaceuticals Inc. | Polymeropoulos Mihael Hristos | Pres, CEO | S - Sale | $18.38 | -22,685 | 1,396,062 | -2% | -$416,905 | |||||
| D | 2021-03-02 | CLVS | Clovis Oncology, Inc. | Harding Thomas C. | See Remarks | S - Sale+OE | $6.29 | -307 | 10,477 | -3% | -$1,931 | |||||
| M | 2021-03-01 | VNDA | Vanda Pharmaceuticals Inc. | Moran Kevin Patrick | SVP, CFO, Treasurer | S - Sale | $18.35 | -9,371 | 102,061 | -8% | -$171,971 | |||||
| D | 2021-03-02 | CLVS | Clovis Oncology, Inc. | Gross Paul Edward | See Remarks | S - Sale+OE | $6.29 | -456 | 43,521 | -1% | -$2,868 | |||||
2021-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Jones Aranthan II | Chief Corp. Affairs Officer | S - Sale | $18.04 | -3,865 | 96,935 | -4% | -$69,717 | ||||||
| M | 2021-03-01 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | S - Sale | $18.28 | -20,465 | 171,708 | -11% | -$374,017 | |||||
| D | 2021-03-02 | CLVS | Clovis Oncology, Inc. | Rolfe Lindsey | See Remarks | S - Sale+OE | $6.29 | -661 | 69,364 | -1% | -$4,158 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |